Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
ASTRAZENECA AB (TW)
ATC Code
C07AB02
Source
TFDA
USDailyMed:Metoprolol
AU:C
C07AB02(WHO)
AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyIn general: ℞ (Prescription only)
(RS)-1-[4-(2-Methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
51384-51-1Y
4171
553
DB00264Y
4027Y
GEB06NHM23
D02358Y
CHEBI:6904Y
ChEMBL13Y
DTXSID2023309
Interactive image
O(c1ccc(cc1)CCOC)CC(O)CNC(C)C
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3YKey:IUBSYMUCCVWXPE-UHFFFAOYSA-NY
Metoprolol, sold under the brand namesLopressorandToprol-XLamong others, is a medication used to treatangina,high blood pressureand a number of conditions involving anabnormally fast heart rate.It is also used to prevent further heart problems aftermyocardial infarctionand to prevent headaches in those withmigraines.It is abeta blocker, specifically a selectiveβ1receptorblocker, and is takenby mouthor is given intravenously.
Common side effects include trouble sleeping,feeling tired, feelingfaint, and abdominal discomfort.Large doses may cause serious toxicity.Risk in pregnancy has not been ruled out.It appears to be safe in breastfeeding.The metabolism of metoprolol can vary widely among patients, often as a result of hepatic impairmentorCYP2D6polymorphism.
Metoprolol was first made in 1969, patented in 1970, and approved for medical use in 1978.It is on theWorld Health Organization's List of Essential Medicines.It is available as ageneric medication.In 2023, it was the sixth most commonly prescribed medication in the United States, with more than 59million prescriptions.
⚠️ Warnings
Metoprolol succinate controlled release (CR)/extended release (XR) plays an important role in the management of Heart Failure with reduced Ejection Fraction (HFrEF) defined by a left ventricular ejection fraction of ≤ 40%. Evidence supports it reduces the incidence of hospitalisation due to cardiovascular events and worsening heart failure when used in combination with other medications in accordance to current prescribing guidelines.However, in some circumstances, particularly when initiating metoprolol in patients with more symptomatic disease, an increased prevalence of hospitalisation and mortality has been reported within the first two months of starting.Patients should monitor for swelling of extremities, fatigue, and shortness of breath.
Given that the evidence from theCochrane Reviewthere is some efficacy of metoprolol as a prevention ofatrial fibrillationrecurrence but not prominent. Further investigation may require assessing the ongoing benefit.
This medicine may cause changes in blood sugar levels or cover up signs of low blood sugar, such as a rapid pulse rate.It also may cause some people to become less alert than they are normally, making it dangerous for them to drive or use machines.
